News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
200,023 Results
Type
Article (6348)
Company Profile (16)
Press Release (193659)
Section
Business (78978)
Career Advice (460)
Deals (15992)
Drug Delivery (16)
Drug Development (16575)
Employer Resources (31)
FDA (2704)
Job Trends (3910)
News (112369)
Policy (6636)
Tag
Academia (332)
Africa (125)
Alliances (10586)
Alzheimer's disease (224)
Approvals (2698)
Arizona (53)
Asia (10667)
Australia (1383)
Bankruptcy (130)
Best Places to Work (3359)
C2C Services and Suppliers (20364)
California (760)
Canada (322)
Cancer (139)
Career advice (399)
Cell therapy (32)
China (31)
Clinical research (13292)
Collaboration (37)
Colorado (34)
Connecticut (33)
COVID-19 (378)
Cystic fibrosis (23)
Data (137)
Diabetes (20)
Diagnostics (1716)
Earnings (44845)
Employer resources (29)
Europe (20193)
Events (38374)
Executive appointments (104)
FDA (2759)
Florida (123)
Funding (55)
Gene therapy (20)
Georgia (25)
GLP-1 (114)
Government (691)
Healthcare (5768)
Hotbed/Location (145629)
Illinois (52)
Indiana (74)
Infectious disease (385)
Inflammatory bowel disease (31)
Interviews (61)
IPO (8995)
Job creations (583)
Job search strategy (354)
Kansas (25)
Layoffs (52)
Legal (1746)
Lung cancer (34)
Maine (29)
Manufacturing (31)
Maryland (144)
Massachusetts (665)
Medical device (4626)
Medtech (4627)
Mergers & acquisitions (7009)
Metabolic disorders (54)
Michigan (69)
Minnesota (92)
Neuroscience (271)
New Hampshire (19)
New Jersey (290)
New York (260)
NextGen Class of 2024 (1897)
Non-profit (564)
North Carolina (284)
Northern California (361)
Obesity (27)
Ohio (37)
Opinion (43)
Patents (22)
Pennsylvania (227)
People (20219)
Phase I (4129)
Phase II (6193)
Phase III (4605)
Pipeline (71)
Postmarket research (312)
Preclinical (1382)
Press Release (18)
Radiopharmaceuticals (103)
Rare diseases (37)
Real estate (1010)
Recruiting (16)
Regulatory (4411)
Reports (18)
Research institute (415)
Resumes & cover letters (58)
South America (271)
Southern California (314)
Startups (961)
Texas (93)
United States (3547)
Utah (25)
Vaccines (70)
Washington State (93)
Weight loss (17)
Date
Today (59)
Last 7 days (209)
Last 30 days (908)
Last 365 days (13818)
2024 (10257)
2023 (15066)
2022 (19111)
2021 (20479)
2020 (18786)
2019 (13541)
2018 (10150)
2017 (9673)
2016 (8629)
2015 (11332)
2014 (8212)
2013 (6182)
2012 (6844)
2011 (6958)
2010 (6212)
200,023 Results for "replay holdings llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
Scilex Holding Company announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC.
June 20, 2024
·
7 min read
Drug Development
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
March 11, 2024
·
5 min read
Deals
INTEGRATED ONCOLOGY NETWORK ANNOUNCES THE ACQUISITION OF UROLOGY PARTNERS, LLC
Integrated Oncology Network, LLC (“ION”), a portfolio company of Silver Oak Services Partners, LLC (“Silver Oak”), today announced the acquisition of Urology Partners, LLC.
May 2, 2024
·
3 min read
BioMidwest
CoagCo LLC Announces Agreement with CHAMPS GPO for its Innovative Nosebleed Device
CoagCo LLC, a Cleveland-based medical device company, announced that it has entered into an agreement with CHAMPS Group Purchasing, a group purchasing organization that leverages the purchasing power of more than 20,000 member locations across the U.S. to support supplier businesses and provide savings to its members.
June 3, 2024
·
2 min read
Press Releases
InfuSystem and Sanara MedTech Inc. Announce Exclusive United States Distribution Agreement with ChemoMouthpiece, LLC
September 11, 2024
·
9 min read
Business
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®
Replay today announced a licensing and manufacturing agreement to support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy targeting the tumor-associated neoantigen, PRAME.
December 18, 2023
·
5 min read
Pharm Country
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
CorMedix Inc. announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath®.
April 8, 2024
·
3 min read
Press Releases
Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
October 1, 2024
·
3 min read
Drug Development
Zavation Medical Products, LLC announces launch of Varisync® ALIF System
September 10, 2024
·
3 min read
Policy
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
Replay and The University of Texas MD Anderson Cancer Center, announced that the Food & Drug Administration has issued a ‘safe to proceed’ for the Investigational New Drug application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer cell therapy for relapsed/refractory myeloid malignancies.
April 30, 2024
·
5 min read
1 of 20,003
Next
